9 completed, 1 unknown. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 9, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow PF-00299804: new trials by email Literature Review of PF-00299804 trials Research Report on PF-00299804
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer Dacomitinib - Skin Squamous Cell Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 43 | 2014-11-01 | 2016-07-04 |
| Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis Dacomitinib - Penile Neoplasms, Carcinoma, Squamous Cell | Phase 2 | Completed | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 32 | 2013-06-15 | 2021-05-14 |
| PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma PF-00299804 - Head Neck Cancer Squamous Cell Metastatic, Head Neck Cancer Squamous Cell Recurrent | Phase 2 | Completed | Yonsei University | 49 | 2011-10-01 | 2014-09-30 |
| PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer PF00299804 - Advanced Gastric Cancer, HER2 | Phase 2 | Completed | Seoul National University Hospital | 28 | 2010-07-01 | 2015-11-20 |
| Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment PF-00299804 - Oral Cavity Cancer | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 13 | 2010-05-01 | 2015-07-10 |
| PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma PF-00299804 - Glioblastoma, GBM | Phase 2 | Completed | Massachusetts General Hospital | 58 | 2010-04-01 | 2018-08-16 |
| Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer PF-00299804 - Head and Neck Neoplasms | Phase 2 | Completed | Pfizer | 69 | 2008-11-04 | 2021-02-09 |
| A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen Erlotinib, PF-00299804 - Non-small Cell Lung Cancer | Phase 2 | Completed | Pfizer | 188 | 2008-11-01 | 2015-10-07 |
| PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 66 | 2008-04-29 | 2019-05-21 |
| Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer PF-00299804 - Carcinoma, Non Small Cell Lung | Phase 2 | Completed | Pfizer | 55 | 2008-02-05 | 2020-10-19 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2) · Glioblastoma (1) · Lung Neoplasms (1) · Mouth Neoplasms (1) · Neoplasm Metastasis (1) · Penile Neoplasms (1) · Recurrence (1)
Pfizer (4) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Massachusetts General Hospital (1) · Seoul National University Hospital (1) · University Health Network, Toronto (1) · Yonsei University (1)
South Korea (4) · Canada (3) · United States (3) · Italy (2) · Australia (1) · Brazil (1) · Hong Kong (1) · Poland (1) · Puerto Rico (1) · Singapore (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Andrea Necchi, MD (1) · Byoung Chul Cho, M.D.,Ph.D. (1) · Lillian Siu, MD, FRCPC (1) · Paolo Bossi, MD (1) · Roberto Salvioni, MD (1) · Tracy T. Batchelor, MD (1) · Yung-Jue Bang, MD, PhD (1)
PMID 24501009, PMID 25057165, PMID 25521398, PMID 26581547, PMID 26768165
2008 (1)